COMMUNIQUÉS West-GlobeNewswire

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
26/01/2026
- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 (GLOBE NEWSWIRE [...]
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conference call on 6 Feb 2026 at 11.00am CET
26/01/2026
Friday, 6 February 2026 at 11:00-12:00am CET In connection with the publication of Coloplast’s interim financial results for Q1 2025/26, to be released same day around 07.30am CET, Coloplast will host a conference call [...]
QHSLab (OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt Reduction
26/01/2026
Revenue increased 25% year over year, gross margins expanded to approximately 67%, and convertible debt was substantially eliminated Improved profitability and early Q-Cog reimbursement activity position the Company for [...]
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
26/01/2026
CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially insured patients Launch [...]
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
26/01/2026
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI [...]
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
26/01/2026
Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and [...]
Indivior Announces Completion of Redomiciliation to the United States
26/01/2026
RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior [...]
BlueOcean Global Announces FDA 510(k) Clearance of the Excelsior™ External Fixation System
26/01/2026
MIAMI, Jan. 26, 2026 (GLOBE NEWSWIRE) -- BlueOcean Global Corp., a medical device company focused on limb preservation and complex reconstruction, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance [...]
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
26/01/2026
10XB-101 Being Developed for Focal Fat Reduction and Body Contouring LA JOLLA, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics, a clinical-stage biotechnology company focused on innovative aesthetic [...]
Cannara publie ses résultats pour le premier trimestre de l’exercice 2026, enregistre de nouveaux résultats financiers records, accroît ses parts de marché et poursuit sa stratégie d’expansion disciplinée
26/01/2026
Nouveaux résultats financiers records : revenus totaux de 30,1 millions de dollars, marge brute avant ajustements de la juste valeur de 13,5 millions de dollars, soit 45 %, et BAIIA ajusté de 8,8 millions de dollars 1 [...]
Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature
26/01/2026
A major technological advance in DNA writing enables researchers to construct and create in the language of biology SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Genyro Inc., a biotechnology company advancing next- [...]
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
26/01/2026
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system [...]
Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
26/01/2026
New Record Financial Results: Total revenues of $30.1 million, gross profit before fair value adjustments of $13.5 million or 45% and Adjusted EBITDA of $8.8 million 1 , supported by operating cash flows of $8.0 million [...]
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
26/01/2026
Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- MannKind [...]
HighLife Receives CE Mark Approval for its TMVR Solution
26/01/2026
HighLife Receives CE Mark Approval for its TMVR Solution Paris, January 26, 2026 – HighLife SAS, a leading MedTech company focused on transcatheter solutions for structural heart disease, today announced that it has [...]
Nxera Pharma Webinar Presentation for FY2025 Financial Results
26/01/2026
Tokyo, Japan and Cambridge, UK, 26 January 2026 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2025 on Friday, 13 February [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
26/01/2026
COPENHAGEN, Denmark, January 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount [...]
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
26/01/2026
Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-point improvement in [...]
Lake Erie College of Osteopathic Medicine Designs Medical Education Around Multiple Learning Pathways to Support Different Learning Styles
26/01/2026
Erie, PA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Medical education is often delivered through a single instructional format, but Lake Erie College of Osteopathic Medicine (LECOM) is taking a different approach by designing [...]

Pages